Drug survival of IL-23 and IL-17 inhibitors versus other biologics for psoriasis: A British Association of Dermatologists Biologics and Immunomodulators Register cohort study

Psoriasis

Age and biologic survival in patients with moderate-to-severe psoriasis: A cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR)

Br J Dermatol

Alabas OA, Mason KJ, Yiu ZZN, Smith CH, Warren RB, Grifﬁths CEM, BADBIR study group

doi: 10.1093/bjd/ljaf017

Psoriasis

Joint Position Statement from the National Psoriasis Foundation Medical Board and the International Psoriasis Council on Routine Testing for Latent Tuberculosis Infection Prior To and During Treatment of Psoriasis Patients with IL-17 or IL-23 Inhibitors

J Am Acad Dermatol

Blauvelt A, Strober BE, Eakin GS, McCormick Howard L, Langan C, van de Kerkhof PCM, Puig L, Lebwohl MG, Romiti R, Armstrong AW, Choon SE, Ramessur R, Gelfand JM, Merola JF, Winthrop KL, Torres T

doi: 10.1016/j.jaad.2025.11.033

Psoriasis

Real-world Drug Survival of Biosimilar SB5 vs GP2017 Following a Mandatory Non-medical Switch from Adalimumab Originator for Psoriasis: A Nationwide Cohort Study

Acta Derm Venereol

Sieborg J, Maul JT, Wu JJ, Loft NN, Skov L, Bryld LE, Rasmussen MK, Dam TN, Bertelsen T, Ajgeiy KK, Thomsen SF, Thyssen JP, Egeberg A, Thein D

doi: 10.2340/actadv.v105.42572

Psoriasis

Drug survival of systemic treatments for severe paediatric psoriasis: An international retrospective study

J Eur Acad Dermatol Venereol

Miao Y, Beauchet A, Piram M, McPherson T, Torres T, Yesli Y, Aubert H, Bodemer C, Bertoli C, Tardieu M, Hubiche T, Bonniaud B, Neri I, Chessa MA, Lasek A, Prignano F, Barbarot S, Bursztejn AC, Leducq S, Sergeant M, Puzenat E, Chiaverini C, Sigg N, Mallet S, Miquel J, Pourchot D, Patel KX, Burden-Teh E, Flohr C, Di Lernia V, Mahé E, GrPso of the Société Française de Dermatologie; Groupe de Recherche de la Société Française de Dermatologie Pédiatrique

doi: 10.1111/jdv.70108

Further Publications Immunology

Association of Cutaneous Immune-related Adverse Events with Overall Survival and Progression-free Survival in Oncology Patients Receiving Immune Checkpoint Inhibitors: A Prospective Study of 189 Patients in a Spanish Tertiary Care Hospital

Acta Derm Venereol

Juan-Carpena G, Martínez Banaclocha N, Palazón Cabanes JC, Niveiro-de Jaime M, Betlloch Mas I, Blanes-Martínez M

doi: 10.2340/actadv.v105.42023

Melanoma and Skin Cancer

St Andrews Referral Delay in Skin Cancer (StARDISC): A study of keratinocyte skin cancer time to treatment, growth, invasiveness, British Association of Dermatologists risk factors and excision adequacy

Br J Dermatol

Miranda BH, Shahid S, Correiro A, Zhang J, Kosasih S, El-Muttardi N

doi: 10.1093/bjd/ljaf097

Psoriatic Arthritis

Higher levels of high-sensitivity CRP are associated with future development of Psoriatic Arthritis in Psoriasis: A prospective cohort study

Arthritis Care Res (Hoboken)

Eder L, Li X, Chandran V, Rosen CF, Cook RJ, Gladman DD

doi: 10.1002/acr.25539

Systemic Sclerosis

Efficacy and safety of rituximab versus intravenous cyclophosphamide for systemic sclerosis-associated interstitial lung disease: a retrospective cohort study

Arthritis Res Ther

Hiura R, Ayano M, Uchino A, Hiura J, Ueda N, Tanaka A, Yoshizawa S, Kawano S, Sagawa F, Ota SI, Hirata A, Fujimoto S, Nishimura N, Takaki-Kuwahara A, Kimoto Y, Akashi K, Niiro H

doi: 10.1186/s13075-025-03654-0

Rheumatoid Arthritis

Incidence of major adverse cardiovascular events in patients with rheumatoid arthritis treated with Janus kinase inhibitors compared to biologic disease-modifying antirheumatic drugs: data from an international collaboration of registries (the "JAK-pot" study)

Arthritis Rheumatol

Aymon R, Mongin D, Guemara R, Salis Z, Askling J, Choquette D, Codreanu C, Di Giuseppe D, Flouri I, Huschek D, Hyrich KL, Iannone F, Kvien TK, Leeb BF, Nordström D, Otero-Varela L, Pavelka K, Pombo-Suarez M, Rodrigues A, Rotar Z, Sidiropoulos P, Provan SA, Strangfeld A, Nina T, Zavada J, Kearsley-Fleet L, Courvoisier DS, Finckh A, Lauper K

doi: 10.1002/art.43188

Related content

Age and biologic survival in patients with moderate-to-severe psoriasis: A cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR)

Joint Position Statement from the National Psoriasis Foundation Medical Board and the International Psoriasis Council on Routine Testing for Latent Tuberculosis Infection Prior To and During Treatment of Psoriasis Patients with IL-17 or IL-23 Inhibitors

Real-world Drug Survival of Biosimilar SB5 vs GP2017 Following a Mandatory Non-medical Switch from Adalimumab Originator for Psoriasis: A Nationwide Cohort Study

Drug survival of systemic treatments for severe paediatric psoriasis: An international retrospective study

Association of Cutaneous Immune-related Adverse Events with Overall Survival and Progression-free Survival in Oncology Patients Receiving Immune Checkpoint Inhibitors: A Prospective Study of 189 Patients in a Spanish Tertiary Care Hospital

St Andrews Referral Delay in Skin Cancer (StARDISC): A study of keratinocyte skin cancer time to treatment, growth, invasiveness, British Association of Dermatologists risk factors and excision adequacy

Higher levels of high-sensitivity CRP are associated with future development of Psoriatic Arthritis in Psoriasis: A prospective cohort study

Efficacy and safety of rituximab versus intravenous cyclophosphamide for systemic sclerosis-associated interstitial lung disease: a retrospective cohort study

Incidence of major adverse cardiovascular events in patients with rheumatoid arthritis treated with Janus kinase inhibitors compared to biologic disease-modifying antirheumatic drugs: data from an international collaboration of registries (the "JAK-pot" study)